ALIVUS (Alivus Life Sciences Limited, formerly Glenmark Life Sciences) - Breakout
Breakout observed in daily timeframe of Alivus, the company has a very good chart pattern and is in a good uptrend and recently broke out with good volumes. The breakout has also been retested and sustained. There could be a good upside in this stock. The company also has good fundamentals as written below.
Fundamentals.
MCap 14,299Cr
Stock P/E 32.4
Industry P/E 31.6
ROCE 28.1%
ROE 21.1%
NPM 20.6%
PEG Ratio 1.69
Debt 16Cr
Reserves 2,514Cr
EPS 36.05
Promoter holding 75%
API contribution 9MFY24
Chronic : 69%
Acute : 31%
Key Therapeutic areas contribution 9MFY24
Diabetes : 4%
CVS : 41%
CNS : 17%
Pain Management : 6%
Others : 32%
Business segments
The company has two key segments - Generics and Complex APIs (92% of FY23 revenue) and Contract Development and Manufacturing Operations (CDMO) (8% of FY23 revenue)
Breakout observed in daily timeframe of Alivus, the company has a very good chart pattern and is in a good uptrend and recently broke out with good volumes. The breakout has also been retested and sustained. There could be a good upside in this stock. The company also has good fundamentals as written below.
Fundamentals.
MCap 14,299Cr
Stock P/E 32.4
Industry P/E 31.6
ROCE 28.1%
ROE 21.1%
NPM 20.6%
PEG Ratio 1.69
Debt 16Cr
Reserves 2,514Cr
EPS 36.05
Promoter holding 75%
API contribution 9MFY24
Chronic : 69%
Acute : 31%
Key Therapeutic areas contribution 9MFY24
Diabetes : 4%
CVS : 41%
CNS : 17%
Pain Management : 6%
Others : 32%
Business segments
The company has two key segments - Generics and Complex APIs (92% of FY23 revenue) and Contract Development and Manufacturing Operations (CDMO) (8% of FY23 revenue)
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.